ADC Therapeutics Q2 Net Loss Narrows to $16.6M; Product Revenue Up
ADC Therapeutics reported a significant narrowing of its net loss for the second quarter of 2026 to $16.6 million, compared to $56.6 million in the prior year. Product revenues saw a modest increase, reaching $18.6 million. However, total revenue for the first half of 2026 decreased to $40.1 million, primarily due to lower license revenues and royalties. The company also amended its royalty purchase agreement with HCR, issuing 9.8 million common share warrants, and recognized $16.6 million in income from the fair value change of this warrant obligation.
Key Highlights
- Net loss for Q2 2026 narrowed to $16.6 million from $56.6 million in Q2 2025.
- Product revenues for Q2 2026 increased to $18.6 million from $18.1 million in Q2 2025.
- Total revenue for H1 2026 was $40.1 million, down from $41.9 million in H1 2025.
- Cash and cash equivalents decreased to $219.1 million as of June 30, 2026, from $261.3 million.
- Issued 9.8 million common share warrants to HCR on February 18, 2026.
- Recognized $16.6 million income from fair value change of warrant obligation in H1 2026.
- R&D expenses for H1 2026 decreased to $37.2 million from $59.0 million in H1 2025.
- Total shareholders' deficit increased to $228.2 million from $185.8 million.
Price Impact
More from ADCT
ADC Therapeutics Q2 Net Loss $16.6M; FDA Raises Concerns on ZYNLONTA LOTIS-5
ADC Therapeutics Grants $2.9M Cash & 1.09M RSU Retention Awards to Executives
ADC Therapeutics Cuts 17% Workforce for $10M Annual Savings